Higlance Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Higlance Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $716.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Higlance Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $716.4K Trade | TransData Nexus

Higlance Laboratories Private Limited

Indian Pharmaceutical Exporter · Advanced Antifungals Specialist · $716.4K Total Trade · DGFT Verified

Higlance Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $716.4K across 3 products in 3 therapeutic categories. Based on 25 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Voriconazole ($475.1K), Bisacodyl ($143.9K), Pseudoephedrine ($97.3K).

Higlance Laboratories Private Limited — Export Portfolio & Destination Treemap

Higlance Laboratories Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Higlance Laboratories Private Limited? — Company Overview & Market Position

Higlance Laboratories Private Limited, established on June 11, 2003, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL2003PTC120847. With an authorized and paid-up capital of ₹6.00 crore, Higlance Laboratories operates as a non-government, unlisted entity.

The company employs approximately 386 professionals as of March 31, 2024. Higlance Laboratories specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to various therapeutic categories. Their product portfolio encompasses anti-diabetic, antimycobacterial, antibacterial, antifungal, antiseptic, antihelmintic, antiprotozoal, antihistamine, anti-inflammatory, analgesic, cardiovascular, cough and cold, and gastrointestinal medications.

What Does Higlance Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Voriconazole$475.1K 2

Product Portfolio — Top 3 by Export Value

Higlance Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Voriconazole	Advanced Antifungals	$475.1K	10	1.5%	14
2	Bisacodyl	Gastrointestinal	$143.9K	12	1.7%	13
3	Pseudoephedrine	Respiratory & OTC	$97.3K	3	0.8%	7

Higlance Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $716.4K. The top category is Advanced Antifungals (66.3% of portfolio), followed by Gastrointestinal (20.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Higlance Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Higlance Laboratories operates a manufacturing plant located in Greater Noida, India. The facility is equipped to produce a diverse range of pharmaceutical products, including tablets, capsules, and soft gelatin capsules. In 2019, the company expanded its production capabilities by establishing a new facility dedicated to soft gelatin capsules, enhancing its manufacturing capacity and product offerings.

3Key Leadership

The leadership team at Higlance Laboratories comprises:

Sanjay Kumar Singh – Managing Director
Ajay Singh – Whole-Time Director
Kalawati Devi – Director

These individuals have been instrumental in steering the company's strategic direction and operational growth since its inception.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Higlance Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Higlance Laboratories has made significant strides in expanding its presence in regulated markets:

United States: The company has initiated the process of obtaining approvals for its products, aiming to enter the U.S. market.

European Union: Higlance Laboratories is in the process of obtaining approvals for its products, targeting entry into the EU market.

United Kingdom: The company is working towards obtaining approvals for its products, with plans to enter the UK market.

Australia: Higlance Laboratories is in the process of obtaining approvals for its products, aiming to enter the Australian market.

Japan: The company is working towards obtaining approvals for its products, targeting entry into the Japanese market.

These efforts reflect Higlance Laboratories' commitment to expanding its global footprint and adhering to international regulatory standards.

Higlance Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, Higlance Laboratories is in the process of obtaining approvals for its products from the U.S. Food and Drug Administration (FDA). The company has initiated the filing of Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs) to meet FDA requirements. While specific details regarding FDA facility registrations and inspection history are not publicly disclosed, the company's proactive approach indicates a commitment to adhering to FDA standards.

2WHO & EU GMP

Higlance Laboratories is in the process of obtaining approvals for its products from the World Health Organization (WHO) and the European Medicines Agency (EMA). The company is working towards obtaining WHO prequalification and EU Good Manufacturing Practice (GMP) certificates to ensure compliance with international quality standards.

3CDSCO & Indian Regulatory

In India, Higlance Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers. The company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its international trade operations.

Higlance Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Higlance Laboratories operates in a competitive pharmaceutical market, facing competition from both domestic and international companies. While specific market share data is not publicly available, the company's focus on diverse therapeutic categories and international expansion positions it to effectively compete in various segments.

2Key Differentiators

Higlance Laboratories distinguishes itself through its commitment to quality and innovation. The development of "Dispersion Technology" for calcium combinations, ensuring early absorption and faster dissolution with a pleasant orange flavor, exemplifies the company's focus on enhancing product efficacy and patient compliance.

3Strategic Position

Higlance Laboratories is strategically positioned as a research-driven pharmaceutical company, focusing on the development and manufacturing of generic medications across various therapeutic areas. The company's future outlook includes expanding its product portfolio, enhancing manufacturing capabilities, and increasing its presence in both regulated and emerging markets.

Buyer Due Diligence Brief — Evaluating Higlance Laboratories Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Higlance Laboratories has demonstrated a consistent track record in manufacturing and exporting pharmaceutical products. The company's export volume and consistency reflect its reliability as a supplier. However, specific reliability indicators are not publicly disclosed.

2Certifications to Verify

Importers should verify the following certifications when considering Higlance Laboratories as a supplier:

FDA Approval: Confirm the company's FDA facility registrations and approved ANDAs.

WHO-GMP Certification: Ensure the company holds WHO prequalification for its products.

EU GMP Certification: Verify the company's compliance with EU Good Manufacturing Practices.

Frequently Asked Questions — Higlance Laboratories Private Limited

How many pharmaceutical products does Higlance Laboratories Private Limited export from India?

Higlance Laboratories Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Voriconazole ($475.1K), Bisacodyl ($143.9K), Pseudoephedrine ($97.3K). Total export value is $716.4K.

What is Higlance Laboratories Private Limited's total pharmaceutical export value?

Higlance Laboratories Private Limited's total pharmaceutical export value is $716.4K, based on 25 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Higlance Laboratories Private Limited cover?

Higlance Laboratories Private Limited exports across 3 therapeutic categories. The largest are Advanced Antifungals (66.3%, 1 products), Gastrointestinal (20.1%, 1 products), Respiratory & OTC (13.6%, 1 products).

Get Full Higlance Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.